Hans Hull - Dec 19, 2022 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role: Chief Business Officer
Signature: /s/ Mike Ouimette, attorney-in-fact
Stock symbol: PLRX
Transactions as of: Dec 19, 2022
Transactions value $: -$167,108
Form type: 4
Date filed: 12/21/2022, 08:32 PM
Previous filing: Feb 2, 2022
Next filing: Jan 27, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLRX	Common Stock	Award	$0	+17.6K	+13.59%	$0.00	147K	Dec 19, 2022	Direct	F1, F2
transaction	PLRX	Common Stock	Sale	-$167K	-8.75K	-5.95%	$19.10	138K	Dec 20, 2022	Direct	F3
holding	PLRX	Common Stock						3.82K	Dec 19, 2022	See footnote	F4
holding	PLRX	Common Stock						14K	Dec 19, 2022	See footnote	F5
holding	PLRX	Common Stock						14K	Dec 19, 2022	See footnote	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 28, 2022, the Reporting Person was granted 70,313 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 17,578 shares.
F2	Includes 4,115 shares of Common Stock acquired by the Reporting Person pursuant to an employee stock purchase program.
F3	The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (3) to this Form 4.
F4	The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5	The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F6	The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.